• KOL
    • Gastric Cancer
    • Han‐ Kwang Yang
    • Han‐ Kwang Yang: Influence Statistics

      Han‐ Kwang Yang

      Han‐ Kwang Yang

      Show email address

      Department of Surgery, Seoul National University Hospital, Seoul 03080, Korea;, pjhaaa1220@gmail.com, (J.-H.P.);, hkyang@snu.ac.kr, (H.-K.Y.) | Cancer Research Institute, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Han‐ Kwang Yang:Expert Impact

      Concepts for whichHan‐ Kwang Yanghas direct influence:Gastric cancer,Distal gastrectomy,Early gastric cancer,Gastric adenocarcinoma,Gastric carcinoma,Lymph node metastasis,Gastric surgery,Lymph node.

      Han‐ Kwang Yang:KOL impact

      Concepts related to the work of other authors for whichfor which Han‐ Kwang Yang has influence:Gastric cancer,Adjuvant chemotherapy,Lymph node,Laparoscopic gastrectomy,Postoperative complications,Stomach neoplasms,Elderly patients.

      KOL Resume for Han‐ Kwang Yang

      Year
      2022

      Department of Surgery, Seoul National University Hospital, Seoul 03080, Korea;, (J.-H.P.);, (H.-K.Y.)

      Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea;

      2021

      Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. Electronic address:

      Cancer Research Institute, Seoul National University College of Medicine, 103 Daehang-Ro, Jongno-gu, 03080, Seoul, Republic of Korea

      2020

      Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

      Cancer Research Institute, Seoul National University College of Medicine, Seoul,

      2019

      Seoul National University College of Medicine, Seoul, Korea, Republic of (South);

      2018

      Cancer Research Institute, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.

      Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul,

      2017

      Department of Surgery, Seoul National University College of Medicine, Seoul, Korea, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

      Cancer Research Institute, Seoul National University College of Medicine, 101 Daehang-Ro, Jongno-gu, 110-744, Seoul, Korea

      2016

      Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; ; Department of Surgery, Seoul National University College of Medicine, Seoul,

      Department of Surgery, Seoul National University College of Medicine, Seoul 110-744, Korea

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Han‐ Kwang Yang is among the top experts in the world.
      Concept World rank
      lowhb postoperative complications #1
      metastases depth #1
      gastric cancer ptnm #1
      lowhb postoperative transfusion #1
      expression tmem220 expression #1
      pof ftr #1
      ca19 342 #1
      capita korea #1
      difference infinity #1
      perigastric #1
      curative resection depth #1
      hdgc lfs #1
      invasive pylorus #1
      respect postoperative qol #1
      discrimination italian cohort #1
      neoplasm staging ldg #1
      plasma expression tff3 #1
      egciib #1
      lymphatic spreading pathway #1
      1057 gastric gists #1
      metastasis multiple egcs #1
      ldg lppg #1
      junction aej #1
      complications gastrectomy #1
      distal gastrectomy advantages #1
      tlppg #1
      dm resection extent #1
      mlapg #1
      depth feasibility studies #1
      gastrectomy type difference #1
      paap stomach #1
      treatment modality mortality #1
      hydrogel 2methoxyestradiol #1
      obesity gastrectomy type #1
      prelated #1
      intraoperative gastroscopy intracorporeal #1
      sidg ldg #1
      fewer complications ladg #1
      treatment prognosis korea #1
      prelated control #1
      operative morbidity snuhnsi #1
      pt2b cancers #1
      nonelderly lateelderly #1
      gastric adenocarcinoma egfr #1
      proximal gastrectomy pg #1
      lifraumeni syndrome case #1
      recurrence ca199 levels #1
      diameter alha #1
      stable purse‐string #1
      invasion ratio #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Han‐ Kwang Yang

      KOL-Index: 20356

      BACKGROUND: Chemotherapy is the standard of care for incurable advanced gastric cancer. Whether the addition of gastrectomy to chemotherapy improves survival for patients with advanced gastric cancer with a single non-curable factor remains controversial. We aimed to investigate the superiority of gastrectomy followed by chemotherapy versus chemotherapy alone with respect to overall survival in these patients.

      METHODS: We did an open-label, randomised, phase 3 trial at 44 centres or ...

      Known for Gastrectomy Chemotherapy | Advanced Gastric | Single Noncurable Factor | 95 Patients | Phase 3
      KOL-Index: 17646

      BACKGROUND: D2 gastrectomy is recommended in US and European guidelines, and is preferred in east Asia, for patients with resectable gastric cancer. Adjuvant chemotherapy improves patient outcomes after surgery, but the benefits after a D2 resection have not been extensively investigated in large-scale trials. We investigated the effect on disease-free survival of adjuvant chemotherapy with capecitabine plus oxaliplatin after D2 gastrectomy compared with D2 gastrectomy only in patients ...

      Known for Adjuvant Capecitabine | Gastrectomy Patients | Randomised Controlled Trial | Chemotherapy Surgery | Gastric Cancer
      KOL-Index: 17551

      BACKGROUND: Adjuvant chemotherapy after surgery improves survival of patients with stage II-III, resectable gastric cancer. However, the overall survival benefit observed after adjuvant chemotherapy is moderate, suggesting that not all patients with resectable gastric cancer treated with adjuvant chemotherapy benefit from it. We aimed to develop and validate a predictive test for adjuvant chemotherapy response in patients with resectable, stage II-III gastric cancer.

      METHODS: In this ...

      Known for Chemotherapy Response | Patients Surgery | Gastric Cancer | Retrospective Analysis | Validation Cohort
      KOL-Index: 17252

      BACKGROUND: The CLASSIC trial was done to compare adjuvant capecitabine plus oxaliplatin versus observation after D2 gastrectomy for patients with stage II or III gastric cancer. The planned interim analysis of CLASSIC (median follow-up 34 months) showed that adjuvant capecitabine plus oxaliplatin significantly improved disease-free survival, the primary endpoint, compared with observation after D2 gastrectomy. We report the 5-year follow-up data from the trial.

      METHODS: CLASSIC was a ...

      Known for Adjuvant Capecitabine | Gastrectomy Patients | Gastric Cancer | Year Follow | Phase 3
      KOL-Index: 15111

      Importance: Laparoscopic distal gastrectomy is gaining popularity over open distal gastrectomy for gastric cancer because of better early postoperative outcomes. However, to our knowledge, no studies have proved whether laparoscopic distal gastrectomy is oncologically equivalent to open distal gastrectomy.

      Objective: To examine whether the long-term survival among patients with stage I gastric cancer undergoing laparoscopic distal gastrectomy is noninferior to that among patients ...

      Known for Distal Gastrectomy | Gastric Cancer | Surgery Stage | Year Survival | Laparoscopic Approach
      KOL-Index: 14474

      Background: Gastric cancer is the most frquent cancer and the leading cause of death from cancer in Korea. Early gastric cancer has been defined as a gastric carcinoma confined to mucosa or submucosa, regardless of lymph node status, and has an excellent prognosis with a >90% 5-year survival rate. From 1974 to 1992, we encountered 7,606 cases of gastric cancer and performed 6,928 gastric resections. Among them, 1,136 cases were early gastric cancer (14.9% of all gastric cancer cases and ...

      Known for Lymph Node Metastasis | Early Gastric Cancer | Prognostic Factor | Depth Invasion | Gastric Carcinoma
      KOL-Index: 14399

      PURPOSE: Gain-of-function mutations and KIT overexpression are well-known tumorigenesis mechanisms in gastrointestinal stromal tumors (GIST). This study aimed to discover microRNAs (miRNA) that target KIT and reveal the relationship between the discovered miRNAs and KIT expression in GISTs.

      EXPERIMENTAL DESIGN: Fresh-frozen GISTs from 31 patients were used to confirm the relationship between miR-494 and KIT expression using quantitative reverse transcription-PCR to assess miR-494 ...

      Known for Kit Expression | Cell Proliferation | Gastrointestinal Stromal | Mir494 Gists | Western Blotting
      KOL-Index: 14071

      BACKGROUND: Although mucin expressions appear to be correlated with prognoses in patients with various cancers, several studies have reported conflicting and inconclusive results on the prognostic significance of mucin expression in gastric carcinomas.

      METHODS: To clarify the correlations between clinicopathologic profiles and the patients' survival, the expression of MUC1, MUC2, MUC5AC, MUC6 mucins and the p53 protein were evaluated immunohistochemically in 300 consecutive gastric ...

      Known for Gastric Carcinomas | Muc1 Muc2 | Mucin Expression | Muc5ac Muc6 | P53 Protein
      KOL-Index: 13833

      AIM: To explore the feasibility of performing minimally invasive surgery (MIS) on subsets of submucosal gastric cancers that are unlikely to have regional lymph node metastasis.

      METHODS: A total of 105 patients underwent radical gastrectomy with lymph node dissection for submucosal gastric cancer at our hospital from January 1995 to December 1995. Besides investigating many clinicopathological features such as tumor size, gross appearance, and differentiation, we measured the depth of ...

      Known for Lymph Node | Submucosal Invasion | Tumor Size | Gastric Cancer | 500 Microm
      KOL-Index: 13832

      BACKGROUND: Two types of cells are cultured from the human peripheral blood, early endothelial progenitor cells (EPCs) and outgrowth endothelial cells (OECs), as previously reported. Here, we further characterize these cells, especially with respect to their different origins and functions both in vitro and in vivo. We also investigated whether the combination of these different cell types shows synergism during neovascularization.

      METHODS AND RESULTS: Early EPCs were heterogeneously ...

      Known for Endothelial Cells | Early Epcs | Nude Neovascularization | Ischemia Matrix | Cell Transplantation
      KOL-Index: 13302

      OBJECTIVE: The aim of the study was to evaluate the short-term outcomes of KLASS-02-RCT, a multicenter randomized controlled trial comparing laparoscopic distal gastrectomy (LDG) with D2 lymphadenectomy with open distal gastrectomy (ODG).

      SUMMARY BACKGROUND DATA: Although several benefits of laparoscopic gastric cancer surgery have been reported, strong evidence is still limited, especially in locally advanced gastric cancer which requires extensive lymph node dissection.

      METHODS: ...

      Known for Distal Gastrectomy | Controlled Trial | Ldg Odg | Advanced Gastric | Shortterm Outcomes
      KOL-Index: 12934

      BACKGROUND: We investigated prognostic differences according to nodal status in patients with pT2a and pT2b stage gastric cancers.

      METHODS: The clinicopathologic outcomes of 1118 patients who underwent curative resection and had 15 or more lymph nodes evaluated for pT2 stage gastric cancers between 1986 and 1996 were reviewed retrospectively. Of the study group, 442 (39.5%) patients had pT2a stage gastric cancers and 676 (60.5%) had pT2b stage gastric cancers.

      RESULTS: The rates of lymph ...

      Known for Pt2 Gastric | Lymph Node | Cancers Patients | Multivariate Analysis | Nodal Status
      KOL-Index: 12912

      Background. Although the results of gastric cancer treatment have markedly improved, this disease remains the most common cause of cancer death in Korea.Methods. Clinicopathologic characteristics were analyzed for 10 783 consecutive patients who underwent operation for gastric cancer at the Department of Surgery, Seoul National University Hospital, from 1970 to 1996. We also evaluated survival and prognostic factors for 9262 consecutive patients operated from 1981 to 1996. The ...

      Known for Gastric Cancer | Resected Lymph Nodes | Curative Resection | Depth Invasion | Lymph Node Metastasis
      KOL-Index: 12498

      BACKGROUND & AIMS: Intestinal metaplasia (IM) and spasmolytic polypeptide-expressing metaplasia (SPEM) are precursors to gastric carcinogenesis. We sought to identify molecular biomarkers of gastric metaplasias and gastric cancer by gene expression profiling of metaplastic lesions from patients.

      METHODS: Complementary DNA microarray analysis was performed on IM and SPEM cells isolated from patient samples using laser capture microdissection. Up-regulated transcripts in metaplastic ...

      Known for Gastric Cancer | Gene Expression | Early Stage | Tumor Cadherins | Metaplastic Lesions

      Key People For Gastric Cancer

      Top KOLs in the world
      #1
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      #2
      Jacques Ferlay
      cancer incidence global burden latin america
      #3
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #4
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #5
      David Forman
      gastric cancer helicobacter pylori eradication therapy
      #6
      Jaffer A Ajani
      gastric cancer esophageal adenocarcinoma preoperative chemoradiation

      Department of Surgery, Seoul National University Hospital, Seoul 03080, Korea;, pjhaaa1220@gmail.com, (J.-H.P.);, hkyang@snu.ac.kr, (H.-K.Y.) | Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea; | Cancer Res

    Download on the App StoreGet it on Google Play

    Copyright © 2023 KOL - Key Opinion Leaders, LLC.

    KOL does not provide medical advice, diagnosis or treatment.